Development of a Nomogram to Integrate Molecular Testing and Clinical Variables to Improve Malignancy Risk Assessment

Jiahui Wu1, Paul Stewardson1, Markus Eszlinger1,2

  • 1Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.

Summary

Integrating molecular testing (MT) with clinical data significantly improves malignancy risk prediction for indeterminate thyroid nodules (ITNs). This combined approach aids in personalized treatment decisions, optimizing surgical intervention for thyroid nodules.